International Cancer Conference Journal最新文献

{"title":"A case of remarkable response to combined radiation therapy, enfortumab vedotin, and pembrolizumab in metastatic urothelial carcinoma.","authors":"Fumihiko Urabe, Keigo Sakanaka, Mana Nakata, Yuma Goto, Katsuki Muramoto, Soshi Kadena, Hajime Onuma, Kosuke Iwatani, Yu Imai, Kojiro Tashiro, Takahiro Kimura, Tatsuya Shimomura","doi":"10.1007/s13691-025-00749-y","DOIUrl":"10.1007/s13691-025-00749-y","url":null,"abstract":"<p><p>Enfortumab Vedotin (EV), an antibody-drug conjugate targeting Nectin-4, combined with pembrolizumab (Pem), has become a first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC). However, the concurrent use of EV + Pem with radiotherapy (RT) remains underexplored. We report the case of a 74-year-old man with a history of robot-assisted radical cystectomy for muscle-invasive bladder cancer. Nine months post-cystectomy, the patient presented with a symptomatic calcified recurrence in the left obturator internus muscle, causing left leg numbness. The patient underwent concurrent EV + Pem therapy and RT (50 Gy in 25 fractions). Treatment was well-tolerated, with only grade 2 alopecia, grade 2 dysgeusia, and grade 1 pruritus observed. Notably, the leg numbness resolved completely by the end of RT, and imaging revealed substantial tumor shrinkage with residual calcification after two cycles of EV + Pem. This case demonstrates that concurrent administration of RT with EV + Pem can achieve significant tumor reduction and symptomatic relief without severe toxicities in la/mUC. This approach may provide a promising therapeutic strategy for managing symptomatic, radiotherapy-accessible lesions in la/mUC, warranting further investigation.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"143-146"},"PeriodicalIF":0.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic progressive pulmonary aspergillosis within the irradiated field after stereotactic body radiotherapy: two case reports.","authors":"Nao Mamuro, Noriko Kishi, Yukinori Matsuo, Masahiro Yoneyama, Hiroyuki Inoo, Minoru Inoue, Takashi Mizowaki","doi":"10.1007/s13691-025-00744-3","DOIUrl":"10.1007/s13691-025-00744-3","url":null,"abstract":"<p><p>Stereotactic body radiation therapy (SBRT) is the standard treatment for patients who are medically inoperable or who refuse surgery with stage I non-small cell lung cancer (NSCLC). While acute lymphopenia following SBRT is documented, the long-term effects on the immune system and infectious disease remain unclear. In this report, we present two cases of chronic progressive pulmonary aspergillosis (CPPA) occurring within the irradiated field following SBRT for inoperable stage I NSCLC. Case 1 was a man in his 70 s with a history of smoking and a previous pulmonary resection and SBRT for metachronous primary lung cancer. He received SBRT for T1aN0M0 NSCLC in the right lower lobe as his third primary lung cancer. After 20 months, the patient developed a cough and sputum, and a computed tomography (CT) scan revealed a cavity shadow in the irradiated field, which led to the diagnosis of CPPA. Intravenous voriconazole was immediately started, and after 3 week's administration, the symptoms improved, and the cavity disappeared. After 34 months, the patient died with no recurrence of CPPA and lung cancer. Case 2 was a man in his 80 s with a history of smoking and previous pulmonary resection for lung cancer. He received SBRT for T1cN0M0 NSCLC in the right lower lobe as his second primary lung cancer. After 19 months, the patient developed a fever, and a CT scan revealed a cavity shadow in the irradiated field, which led to the diagnosis of CPPA. Oral itraconazole was administered, followed by diarrhea and anorexia. After 22 days, the patient died. During the follow-up period, there was no recurrence of lung cancer. Risk factors for CPPA include a history of smoking and lung resection, common among candidates for pulmonary SBRT. When a cavity shadow develops following SBRT, differentiating consolidation as radiation pneumonitis, local recurrence, or infection can be challenging. When a cavity is identified on a follow-up CT scan after SBRT, it is crucial to include CPPA in the differential diagnosis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"113-118"},"PeriodicalIF":0.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracoscopic right apical segmentectomy in a patient with tracheal bronchus: a case report and review of literature.","authors":"Yukino Tateno, Tomohiro Yazawa, Toshiteru Nagashima, Yoichi Ohtaki, Natsuko Kawatani, Ryohei Yoshikawa, Eiji Narusawa, Ken Shirabe","doi":"10.1007/s13691-025-00746-1","DOIUrl":"10.1007/s13691-025-00746-1","url":null,"abstract":"<p><p>A 70-year-old female patient was referred to our department for further abnormal chest shadow assessment in the right upper lung field. Computed tomography (CT) imaging detected multiple ground-glass nodules, resulting in primary lung cancer suspicion with no evidence of nodal involvement or distant metastasis. Three-dimensional CT revealed the presence of tracheal bronchus, directly branching off the right B1 bronchus from the trachea. Anomalous venous return was not observed. The patient was preoperatively diagnosed with cStage IA1 lung adenocarcinoma (cT1miN0M0) and underwent thoracoscopic S1 segmentectomy of the right upper lobe. Apical segmental bronchus was directly resected from the trachea, as expected based on preoperative CT examination. Pathologic diagnosis was pStage IA1 lung adenocarcinoma (pT1miN0M0). Multiple synchronous primary lung cancers were observed. The postoperative course was uneventful, and the patient demonstrated no recurrence at the 3-year postoperative follow-up. Tracheal bronchus is a rare abnormality observed in only 1% of patients undergoing thoracic surgery. Thoracic surgeons should be aware that preoperative planning based on three-dimensional CT is crucial in patients with tracheal bronchus because of potential issues associated with anomalous venous return. Good planning will contribute to safe segmentectomy in such cases.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"119-123"},"PeriodicalIF":0.5,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term conservative treatment of chylous ascites in gynecological malignant surgery: a case report and literature review.","authors":"Mayumi Kamata, Yoichi Aoki, Ai Ikki, Atsushi Murakami, Hiroyuki Kanao","doi":"10.1007/s13691-024-00738-7","DOIUrl":"10.1007/s13691-024-00738-7","url":null,"abstract":"<p><p>Chylous ascites is a rare complication of abdominal surgery. Although most patients show improvement with conservative treatment. Long-term leakage of chylous ascites can cause malnutrition, dehydration, and immunosuppression; therefore, an early cure is desirable, but no standard treatment for chylous ascites has been established, and determining the timing of surgical intervention is difficult. A 74-year-old woman underwent surgery for carcinosarcoma of the fallopian tube, including dissection of the pelvic and para-aortic lymph nodes. She was noted to have a large amount of chylous ascites postoperatively. Furthermore, a low-fat diet, weekly ascites punctures and lymphangiography were performed. However, the leakage was not resolved. After ten weeks of intensive treatment with fasting, total parenteral nutrition (TPN), octreotide, etilefrine, and fibrogammin, beginning 18 weeks postoperatively, the chylous ascites changed to serous and disappeared. Long-term conservative treatment may improve chylous ascites, and continued conservative treatment without surgical intervention is an option. The patient was resistant to a low-fat diet, although fasting and TPN were effective. In addition, a change in the color of the ascites from milky white to serous as a precursor to improvement of the erosive ascites may help to consider the timing of surgical intervention.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"79-84"},"PeriodicalIF":0.5,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Squamous cell carcinoma in a long-standing suprapubic cystostomy: a urological oddball.","authors":"Rajat Choudhari, Kamal Kishor Lakhera, Suresh Singh, Pinakin Patel, Naina Kumar, Yashasvi Patel","doi":"10.1007/s13691-024-00743-w","DOIUrl":"10.1007/s13691-024-00743-w","url":null,"abstract":"<p><p>Squamous cell carcinoma (SCC) rarely accounts for 2-5% of urinary bladder cancer. Chronic irritation of the bladder from infection or indwelling catheter is a risk factor for SCC. Only a handful of cases of suprapubic cystostomy (SPC) site SCC have been reported and have been always seen in paraplegics or urethral stricture requiring long-standing catheterization. We report a case of a 69-year-old male with an indwelling (SPC) of 25 years duration for a urethral stricture who presented with a fungating growth around the SPC site enveloping the catheter confirmed to be squamous cell carcinoma. Imaging revealed involvement of abdominal wall and urinary bladder with no metastatic spread. He underwent wide local excision (WLE) of the lesion with radical cystectomy and ileal conduit reconstruction with bilateral ilio-inguinal lymphadenectomy and pedicled anterolateral thigh flap for abdominal wall reconstruction. He received adjuvant radiotherapy and was found to be recurrence free at 3 months. Among the cases previously reported, 9 of the 12 cases were treated surgically with 4 of those combined with partial cystectomy and 4 with radical cystectomy. SPC site SCC tends to be localized around the catheter and into the abdominal tract and wide surgical excision offers the best hope for cure. Regular cystoscopy and biopsy from bladder around the catheter site can help early detection and the treatment should be personalized to each patient.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"107-112"},"PeriodicalIF":0.5,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistant PRL-secreting PitNET associated with breast carcinoma: a case report and literature review.","authors":"Roxana-Ioana Dumitriu-Stan, Iulia-Florentina Burcea, Valeria Nicoleta Nastase, Raluca Amalia Ceausu, Marius Raica, Catalina Poiana","doi":"10.1007/s13691-024-00741-y","DOIUrl":"10.1007/s13691-024-00741-y","url":null,"abstract":"<p><p>In several studies, hyperprolactinemia has been associated with increased breast cancer risk. Evidence shows that prolactin (PRL) is linked to mammary tumorigenesis, especially in postmenopausal patients, but the data remain controversial. We present a case of a 67 year-old patient with a resistant PRL-secreting PitNET who subsequently developed breast cancer. The patient was known to have persistent high PRL levels despite multimodal treatment (surgery, radiotherapy, and high doses of cabergoline). The tumor specimens obtained after transsphenoidal intervention were histologically and immunohistochemically examined for the following parameters: anterior pituitary hormones, the ki-67 labeling index, CAM 5.2 expression, ER ∝ expression, and somatostatin receptors, which revealed a densely granulated tumor with intense positivity for PRL and ER ∝ , a ki-67 labeling index of 6% and negative MGMT expression. Years later, the patient was diagnosed with breast carcinoma. Histopathological and immunohistochemical examination of the tumor specimen obtained after radical mastectomy confirmed ductal invasive breast cancer with negative immunostaining for prolactin receptors (PLRr) but positive immunostaining for estrogen (ER) and progesterone receptors (PGR) and a ki-67 labeling index of 8%. PRL is involved in mammary development and differentiation, which leads to lactation, the major driver during pregnancy, by regulating ovarian progesterone production. On the basis of the physiological actions of PRL, a role for this hormone in breast cancer has been suggested. Few cases of different types of breast carcinoma associated with hyperprolactinemia due to a pituitary tumor have been reported in the literature. The association between hyperprolactinemia and the risk of breast carcinoma is not well understood. Immunohistochemistry evaluation of PLRr can be helpful to provide information in these cases.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"97-106"},"PeriodicalIF":0.5,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anastrozole-induced interstitial lung disease followed by tamoxifen-induced agranulocytosis in a patient with breast cancer.","authors":"Maki Juge, Takako Imada, Mizuki Hirose, Ken Sato","doi":"10.1007/s13691-024-00742-x","DOIUrl":"10.1007/s13691-024-00742-x","url":null,"abstract":"<p><p>A 70-year-old woman with the breast cancer exhibited interstitial lung disease 20 months after the administration with anastrozole, which was performed as the post-operative adjuvant therapy. The drug-induced lymphocyte stimulation test revealed that anastrozole was responsible for the development of interstitial lung disease in this patient. The interstitial lung disease was effectively treated by prednisolone. Then, tamoxifen was used as an alternative therapy, resulting in the occurrence of agranulocytosis 24 days after the administration with tamoxifen. Both anastrozole and tamoxifen are widely used and are highly effective drugs for the treatment of breast cancer. However, the current patient shows that both drugs could cause, albeit very rare, serious side effects in some patients.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"91-96"},"PeriodicalIF":0.5,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors.","authors":"Akiho Nagayama, Chiho Miyagawa, Yoko Kashima, Mamiko Ohta, Tomoyuki Otani, Takashi Kurosaki, Kohsuke Isomoto, Chiaki Inagaki, Takayuki Takahama, Kimio Yonesaka, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa, Noriomi Matsumura","doi":"10.1007/s13691-024-00740-z","DOIUrl":"10.1007/s13691-024-00740-z","url":null,"abstract":"<p><p>A 69-year-old multiparous postmenopausal woman had undergone bilateral total hip arthroplasty 17 years ago. Computed tomography showed a mature teratoma of 10 cm in the pelvis. Subsequently, she presented with symptoms of hoarseness and weight loss, along with evidence of malignant transformation of the same tumor in the pelvis and multiple enlarged lymph nodes. Bilateral adnexectomy was performed via laparotomy, yet peritoneal dissemination persisted. The ovarian tumor's histopathological diagnosis was mature teratoma with squamous cell carcinoma. Additionally, the mediastinal lymph nodes biopsy revealed poorly differentiated carcinoma. Comprehensive genomic profiling testing of the ovarian tumor showed pathogenic variants of <i>TP53</i> and <i>PTEN</i>, a high tumor mutational burden, homologous recombination deficiency and the absence of human papilloma virus. The similar genomic testing of the mediastinal tumor revealed three variants of uncertain significance that were common to the ovarian tumor. However, no variants of <i>TP53</i> or <i>PTEN</i> were identified. Following surgery, she demonstrated a partial response to six cycles of conventional paclitaxel and carboplatin. She then received maintenance treatment with niraparib; however, disease progression subsequently occurred. The patient was treated with pembrolizumab and is currently receiving treatment with a partial response. Previous reports have demonstrated the efficacy of immune checkpoint inhibitors in 5 out of 6 cases of malignant transformation of mature teratomas, and this treatment appears to be a promising strategy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-024-00740-z.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"85-90"},"PeriodicalIF":0.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal anastomotic leakage after conversion surgery for advanced endometrial cancer treated with lenvatinib plus pembrolizumab: a case report.","authors":"Akitoshi Yamamura, Junzo Hamanishi, Koji Yamanoi, Masumi Sunada, Mana Taki, Rin Mizuno, Yukiko Okada, Ryusuke Murakami, Yuki Aisu, Hisatsugu Maekawa, Ken Yamaguchi, Masaki Mandai","doi":"10.1007/s13691-024-00739-6","DOIUrl":"https://doi.org/10.1007/s13691-024-00739-6","url":null,"abstract":"<p><p>The combination therapy of lenvatinib plus pembrolizumab (LP) is increasingly recognized as an important second-line regimen for advanced or recurrent endometrial cancer (EC). However, the safety and efficacy of conversion surgery with low anterior rectal resection for unresectable EC following LP therapy is unknown. A 37-year-old woman was referred with unresectable EC with pleural fluid, peritoneal dissemination, and ascites. After the failure of first-line platinum-based chemotherapy, she was administered LP as second-line treatment. After 10 treatment cycles, uterine and peritoneal tumors significantly reduced in size, except the left ovarian metastatic tumor which became slightly larger. Cytoreductive surgery, including low anterior resection of the rectum and colorectal anastomosis, achieved complete resection. However, on postoperative day 11, the patient experienced an anastomotic leakage around the colorectal anastomosis site, necessitating a double-barreled colostomy and percutaneous drainage. She was discharged 15 days after the second surgery and resumed LP therapy after 44 days following the second surgery. We report a case in which conversion surgery after LP therapy was conducted for unresectable advanced endometrial cancer. Our findings indicate that if bowel resection is required, a longer preoperative withdrawal period may be necessary to prevent postoperative anastomotic leakage.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"64-71"},"PeriodicalIF":0.5,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma.","authors":"Yumi Inukai-Motokura, Kiichiro Ninomiya, Takahiro Baba, Hiroki Omori, Tetsuya Takeguchi, Mari Uno, Yoshiyuki Ayada, Takehiro Tanaka, Yoshinobu Maeda, Kadoaki Ohashi","doi":"10.1007/s13691-024-00737-8","DOIUrl":"https://doi.org/10.1007/s13691-024-00737-8","url":null,"abstract":"<p><p>Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an <i>AKT1</i> E17K mutation, characteristic of PSP, and absence of programmed cell death ligand 1 (PD-L1) expression in the tumor. Two years post-recurrence, the tumor recurred in the left mammary gland and mediastinal lymph nodes. Combination immunotherapy with ipilimumab and nivolumab yielded a significantly positive response in this metastatic PSP case. This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab, following the failure of various local treatments. Further case series are warranted to validate the efficacy of immunotherapy in metastatic PSP.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 1","pages":"60-63"},"PeriodicalIF":0.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}